Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists
Abstract Background The goal of mucoactive therapies in cystic fibrosis (CF) is to enhance sputum clearance and to reduce a progressive decline in lung function over the patient's lifetime. We aimed to investigate the level of consensus among specialists from Italian CF Centers on appropriatene...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-07-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.604 |
| _version_ | 1828321989452890112 |
|---|---|
| author | Sonia Volpi Vincenzo Carnovale Carla Colombo Valeria Raia Francesco Blasi Giovanni Pappagallo PULMOCARE TEAM |
| author_facet | Sonia Volpi Vincenzo Carnovale Carla Colombo Valeria Raia Francesco Blasi Giovanni Pappagallo PULMOCARE TEAM |
| author_sort | Sonia Volpi |
| collection | DOAJ |
| description | Abstract Background The goal of mucoactive therapies in cystic fibrosis (CF) is to enhance sputum clearance and to reduce a progressive decline in lung function over the patient's lifetime. We aimed to investigate the level of consensus among specialists from Italian CF Centers on appropriateness of therapeutic use of dornase alfa (rhDNase) for CF patients. Method A consensus on appropriate prescribing in CF mucoactive agents was appraised by an online Delphi method, based on a panel of 27 pulmonologists, coordinated by a Scientific Committee of six experts in medical care of patients with CF. Results Full or very high consensus was reached on several issues related to therapeutic use of dornase alfa for CF patients in clinical practice. Conclusions The consensus reached on a number of topics regarding use of mucoactive agents in patients with CF can help guide clinicians in daily practice based on expert experience and define the most appropriate therapeutic strategy for the individual patient. |
| first_indexed | 2024-04-13T18:35:20Z |
| format | Article |
| id | doaj.art-a0efc3f6584d44ef94a25cf714e2611b |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-04-13T18:35:20Z |
| publishDate | 2022-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-a0efc3f6584d44ef94a25cf714e2611b2022-12-22T02:34:55ZengWileyHealth Science Reports2398-88352022-07-0154n/an/a10.1002/hsr2.604Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialistsSonia Volpi0Vincenzo Carnovale1Carla Colombo2Valeria Raia3Francesco Blasi4Giovanni Pappagallo5PULMOCARE TEAMCystic Fibrosis Center Azienda Ospedialiera Universitaria Integrata Verona ItalyFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Cystic Fibrosis Center Milan ItalyDepartment of Translational Medical Science, Cystic Fibrosis Centre, Adult Unit University “Federico II” Naples ItalySection of Pediatrics, Department of Translational Medical Sciences “University Federico II” Naples ItalyDepartment of Internal Medicine Respiratory Unit and Adult Cystic Fibrosis Center Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano Milan ItalyPrivate Epidemiologist Silea ItalyAbstract Background The goal of mucoactive therapies in cystic fibrosis (CF) is to enhance sputum clearance and to reduce a progressive decline in lung function over the patient's lifetime. We aimed to investigate the level of consensus among specialists from Italian CF Centers on appropriateness of therapeutic use of dornase alfa (rhDNase) for CF patients. Method A consensus on appropriate prescribing in CF mucoactive agents was appraised by an online Delphi method, based on a panel of 27 pulmonologists, coordinated by a Scientific Committee of six experts in medical care of patients with CF. Results Full or very high consensus was reached on several issues related to therapeutic use of dornase alfa for CF patients in clinical practice. Conclusions The consensus reached on a number of topics regarding use of mucoactive agents in patients with CF can help guide clinicians in daily practice based on expert experience and define the most appropriate therapeutic strategy for the individual patient.https://doi.org/10.1002/hsr2.604cystic fibrosisDelphi methoddornase alfamucoactive agents |
| spellingShingle | Sonia Volpi Vincenzo Carnovale Carla Colombo Valeria Raia Francesco Blasi Giovanni Pappagallo PULMOCARE TEAM Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists Health Science Reports cystic fibrosis Delphi method dornase alfa mucoactive agents |
| title | Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists |
| title_full | Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists |
| title_fullStr | Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists |
| title_full_unstemmed | Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists |
| title_short | Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists |
| title_sort | use of mucoactive agents in cystic fibrosis a consensus survey of italian specialists |
| topic | cystic fibrosis Delphi method dornase alfa mucoactive agents |
| url | https://doi.org/10.1002/hsr2.604 |
| work_keys_str_mv | AT soniavolpi useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists AT vincenzocarnovale useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists AT carlacolombo useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists AT valeriaraia useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists AT francescoblasi useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists AT giovannipappagallo useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists AT pulmocareteam useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists |